Cargando…

In Reply: Neoadjuvant TKI Study in Early- and Intermediate Stage Hepatocellular Carcinoma

This letter to the editor responds to comments from Rizzo et al on recently reported results of a phase II study of dovitinib therapy for hepatocellular carcinoma.

Detalles Bibliográficos
Autores principales:	Osanto, Susanne, Woei-A-Jin, F J Sherida H, Coenraad, Minneke J, Weijl, Nir I, Burgmans, Mark C, Burggraaf, Jacobus
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2022
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9732251/ https://www.ncbi.nlm.nih.gov/pubmed/36269167 http://dx.doi.org/10.1093/oncolo/oyac215

Ejemplares similares

Neoadjuvant Treatment with Angiogenesis‐Inhibitor Dovitinib Prior to Local Therapy in Hepatocellular Carcinoma: A Phase II Study
por: Woei‐A‐Jin, F.J. Sherida H., et al.
Publicado: (2021)

Neoadjuvant Dovitinib in Early- and Intermediate-Stage Hepatocellular Carcinoma
por: Rizzo, Alessandro, et al.
Publicado: (2022)

Reply: ‘Comment on Prevalence of the metabolic syndrome and cardiovascular disease risk in chemotherapy-treated testicular germ cell tumour survivors'
por: Willemse, P M, et al.
Publicado: (2013)

Reply: Comment on ‘Chemotherapy for testicular cancer induces acute alterations in diastolic heart function'
por: van Schinkel, L D, et al.
Publicado: (2014)

Differences in Patient Characteristics and Midterm Outcome Between Asian and European Patients Treated with Radiofrequency Ablation for Hepatocellular Carcinoma
por: Burgmans, Mark Christiaan, et al.
Publicado: (2016)

Tissue factor-bearing microparticles and CA19.9: two players in pancreatic cancer-associated thrombosis?
por: Woei-A-Jin, F J Sherida H, et al.
Publicado: (2016)

Reply
por: Zhang, Yi, et al.
Publicado: (2019)

Commentary: Anatomic resection after neoadjuvant TKI therapy—To be forewarned
por: Chang, Andrew C.
Publicado: (2021)

Prevalence of the metabolic syndrome and cardiovascular disease risk in chemotherapy-treated testicular germ cell tumour survivors
por: Willemse, P M, et al.
Publicado: (2013)

Prevalence of the metabolic syndrome and cardiovascular disease risk in chemotherapy-treated testicular germ cell tumour survivors
por: Willemse, P M, et al.
Publicado: (2013)

Reply to: “Malignant transformation of hepatocellular adenoma”
por: Chopinet, Sophie, et al.
Publicado: (2022)

Multiparametric MRI in Patients With Nonalcoholic Fatty Liver Disease
por: Schaapman, Jelte J., et al.
Publicado: (2020)

Authors’ reply
por: Alkhalili, Eyas, et al.
Publicado: (2017)

Unfavorable metabolic changes are accompanied by impaired myocardial function shortly after chemotherapy
por: Van Der Meer, RW, et al.
Publicado: (2013)

Management of patients with intermediate stage hepatocellular carcinoma
por: Prince, David, et al.
Publicado: (2020)

An exploratory first‐in‐man study to investigate the pharmacokinetics and safety of liposomal dexamethasone at a 2‐ and 1‐week interval in patients with metastatic castration resistant prostate cancer
por: Vrouwe, Josephina P. M., et al.
Publicado: (2021)

Reply: A morpho-molecular prognostic model for hepatocellular carcinoma
por: Srivastava, S, et al.
Publicado: (2013)

Reply: Bayesian analysis supports the role of neoadjuvant chemoradiation followed by surgery for resectable locoregional esophageal cancer
por: Bao, Yongxing, et al.
Publicado: (2022)

Reply: CD133 expression in different stages of gastric adenocarcinoma
por: Smith, L M, et al.
Publicado: (2009)

Intermediate stage hepatocellular carcinoma: a summary review
por: Elshaarawy, Omar, et al.
Publicado: (2019)

Reply to Comment on ‘Diagnosis of pathological complete response to neoadjuvant chemotherapy in breast cancer by minimal invasive biopsy techniques'
por: Heil, Joerg
Publicado: (2016)

Reply to: Biochemical failure after radical prostatectomy in intermediate-risk group men increases with the number of risk factors
por: Arora, Sohrab
Publicado: (2017)

Author’s reply: MRI in T staging of rectal cancer: How effective is it?
por: Mulla, Mubashir
Publicado: (2011)

TKI safety
por: Hjorth-Hansen, Henrik
Publicado: (2019)

Reply to ‘Comment on ‘Transarterial chemo-embolisation of hepatocellular carcinoma: impact of liver function and vascular invasion’ ’
por: Waked, Iman, et al.
Publicado: (2017)

Reply to: Comment on ‘Tumour antigen expression in hepatocellular carcinoma in a low-endemic western area'
por: Sideras, Kostandinos, et al.
Publicado: (2016)

Reply: Adjuvant chemoradiotherapy is no alternative to intensified neoadjuvant chemoradiotherapy for local and systemic control in patients with locally advanced rectal cancer
por: Klautke, G, et al.
Publicado: (2006)

In Reply: Overall Survival of Resectable Metastatic Colon Cancer Treated With Neoadjuvant Chemotherapy or Adjuvant Chemotherapy in Non-academic Program
por: Hao, Zhonglin, et al.
Publicado: (2023)

Reply
por: Hirsova, Petra, et al.
Publicado: (2015)

Reply
por: Rasmussen, Sonja A., et al.
Publicado: (2020)

The complexity of immune cell landscape in hepatocellular carcinomas with different risks—reply letter
por: Tang, Xiaofeng, et al.
Publicado: (2020)

Reply
por: Berlana, David, et al.
Publicado: (2022)

Oncofetal Protein CRIPTO Is Involved in Wound Healing and Fibrogenesis in the Regenerating Liver and Is Associated with the Initial Stages of Cardiac Fibrosis
por: Karkampouna, Sofia, et al.
Publicado: (2021)

Reply()
por: Barrios-López, J.M., et al.
Publicado: (2021)

Reply: Comment on 'Stage-dependent alterations of the serum cytokine pattern in colorectal carcinoma'
por: Kantola, T, et al.
Publicado: (2013)

Reply to ‘Comment on ‘Nomogram to predict pathologic complete response in HER2-positive breast cancer treated with neoadjuvant systemic therapy''
por: Fujii, Takeo, et al.
Publicado: (2017)

In Reply
por: Brennen, W. Nathaniel, et al.
Publicado: (2019)

In Reply
por: Coomes, Eric A., et al.
Publicado: (2020)

Authors’ reply
por: Vaishya, Richa, et al.
Publicado: (2010)

Author's Reply
por: Salz, David A., et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_ecje0kfs17abedfsab8vde1cdh